2024-10-18 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutrition products.

**Performance Analysis:**

1. **Relative Performance:** 
    * ABT's cumulative return is 110.95%, while the S&P 500 (VOO) has returned 136.93%. 
    * This puts ABT at a **-25.98% underperformance** compared to the S&P 500.
    * The **relative underperformance** currently sits at **15.85%**, indicating that it is relatively underperforming compared to its historical performance against the S&P 500. 

2. **Price Momentum:**
    * **Closing Price:** $117.82
    * **5-day Moving Average:** $116.62
    * **20-day Moving Average:** $114.34
    * **60-day Moving Average:** $112.50 
    * ABT's price is currently above all moving averages, suggesting potential positive momentum.

3. **Technical Indicators:**
    * **RSI:** 72.22 - Indicates that the stock is currently in overbought territory.
    * **PPO:** 0.27 -  Suggests that the stock's price is trending upwards.
    * **Delta_Previous_Relative_Divergence:** -2.46 - Suggests a short-term downtrend in relative performance.
    * **Expected_Return:** 0.0% - This indicates that over the next 5 years, the stock is expected to yield a 0% return above the S&P 500.

4. **Recent Earnings and Outlook:**

| Date        | EPS     | Revenue       |
|-------------|---------|---------------|
| 2024-07-31 | 0.74    | 10.38 B$      |
| 2024-05-02 | 0.70    | 9.96 B$      |
| 2023-11-01 | 0.82    | 10.14 B$      |
| 2023-08-03 | 0.79    | 9.98 B$      |
| 2024-07-31 | 0.79    | 9.98 B$      |

* **Most Recent Earnings:** The latest earnings for the quarter ending July 31st, 2024, were reported at $0.74 EPS, beating analysts' expectations.  Revenue was also strong at $10.38 billion, exceeding analysts' predictions.  

**News and Recent Issues:**

* **Recent Market Outlook:** According to FINBOLD, analysts remain optimistic about ABT's long-term prospects, citing its strong product portfolio and expanding global presence. However, concerns about competition and rising costs may put pressure on near-term growth.
* **Analyst Opinions:** Analysts generally have a "Hold" or "Buy" rating on ABT.  
* **Performance Highlights:**  ABT has outperformed the S&P 500 in the long run but has seen some recent weakness due to macroeconomic headwinds and competition within the healthcare industry.

**Conclusion:**

While ABT has exhibited strong earnings performance in the most recent quarter, it currently faces challenges due to competition and cost pressures. Despite showing positive momentum with its price above all moving averages, the stock is overbought according to its RSI and its relative performance against the S&P 500 is lagging.  Investors should continue to monitor ABT's progress in addressing these challenges and its ability to maintain its long-term growth trajectory. 
